Biotech Startup Neobe Therapeutics raises $6.8M Seed Round
Updated: 3 hours ago
Startup Investment News - Biotech Startup Neobe Therapeutics just raised USD 6.8 million in a Seed Round led by Arc Ventures with the participation of Faber, Macmillan Ventures - the investment arm of Macmillan Cancer Support, Proven Connect - the investment arm of Prostate Cancer Research, Empirical Ventures, and strategic angel investors as well as follow-on investment from pre-seed investors 2048 Ventures, bringing the total funding raised by Neobe Therapeutics to more than USD 10.5 million. The new funding will advance the vision of Neobe Therapeutics that is to make untreatable cancers curable.
What is Biotech Startup Neobe Therapeutics?
Portuguese Biotech Startup Neobe Therapeutics built a unique platform that uses engineered harmless strains of common bacteria to break down the physical barriers preventing immunotherapy and other drugs from entering into solid tumours and killing cancer cells. Once injected, they travel specifically to tumours and release enzymes that dissolve the surrounding matrix, effectively breaking through the wall and allowing immune cells or other drugs to enter and eliminate the cancer cells.
The preclinical data of Neobe Therapeutics is compelling, and this funding announced on November 10th, 2026, will enable the Biotech startup to take their lead programme NEO22 through preclinical studies for an IND filing in 2028, while enhancing the leadership team as the company moves towards clinical trials.
"Several treatments that can cure cancer already exist, but in far too many patients they simply cannot get to where they are needed. I’m delighted to be working with investors that share our vision of making untreatable cancers curable, and excited to move our platform towards clinical trials.” - Co-founder and CEO of Neobe Therapeutics, Dr Pedro Correa de Sampaio.
According to Joe Korff, the Founder of Arc Ventures, that is backing Neobe Therapeutics, their differentiated approach to overcoming the physical barriers created by dense tumour matrices and their platform will improve the efficacy of cancer therapies while extending their benefits to more patients.
